Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792332 | 1.00 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL18540883 | 0.81 | MGLL (0.34) | MGLL | |
| SCHEMBL863100 | 0.79 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL1541732 | 0.79 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL2146991 | 0.77 | MGLL (0.34) | MGLL | |
| SCHEMBL17430432 | 0.76 | MGLL (0.36) | MGLLGLA | |
| SCHEMBL258692 | 0.76 | MGLL (0.36) | MGLLGLA | |
| SCHEMBL18908274 | 0.75 | MGLL (0.35) | MGLLGLA | |
| SCHEMBL13551294 | 0.75 | MGLL (0.35) | MGLLGLA | |
| SCHEMBL18908216 | 0.74 | GLA (0.34) | MGLLGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701950-B1 | ECSTASY HAPTENS AND IMMUNOGENS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20120039843-A1 | CONJUGATES OF A POLYPEPTIDE AND AN OLIGOSACCHARIDE | N.V. ORGANON (NL) | 2012-02-16 | — | — | US | disclosed |
| US-8106007-B2 | Having affinity to antithrombin III; improved pharmacokinetic properties when compared to the original polypeptides | N.V. ORGANON (NL) | 2012-01-31 | — | — | US | disclosed |
| US-7863427-B2 | Immunoassays for buprenorphine and norbuprenorphine | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2264464-A2 | Immunoassays for buprenorphine and norbuprenorphine | Siemens Healthcare Diagnostics Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1701950-A4 | ECSTASY HAPTENS AND IMMUNOGENS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080268453-A1 | Types of lymphoma and method for prognosis thereof | AICHI PREFECTURE (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1976563-A2 | CONJUGATES OF A POLYPEPTIDE AND AN OLIGOSACCHARIDE | N.V. Organon (NL) | 2008-10-08 | — | — | EP | disclosed |
| US-20080139459-A1 | Conjugates A Polypeptide And A Pentasaccharide | N.V. ORGANON (NL) | 2008-06-12 | — | — | US | disclosed |
| EP-1756570-A4 | IMMUNOASSAYS FOR BUPRENORPHINE AND NORBUPRENORPHINE | DADE BEHRING INC (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2005103697-A2 | IMMUNOASSAYS FOR BUPRENORPHINE AND NORBUPRENORPHINE | DADE BEHRING INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050221405-A1 | Immunoassays for buprenorphine and norbuprenorphine | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005061482-A1 | ECSTASY HAPTENS AND IMMUNOGENS | DADE BEHRING INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050130225-A1 | Ecstasy haptens and immunogens | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-06-16 | — | — | US | disclosed |
| US-20040214171-A1 | Cat kidney disease marker | TOHOKU TECHNO ARCH CO., LTD. | 2004-10-28 | — | — | US | disclosed |
| EP-0540612-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | Pharmacia AB (SE) | 1993-05-12 | — | — | EP | disclosed |
| EP-0276516-B1 | NEW OLIGOSACCHARIDES, IMMUNOGENS AND VACCINES, AND METHODS FOR PREPARING SUCH OLIGOSACCHARIDES, IMMUNOGENS AND VACCINES | De Staat der Nederlanden, represented by the Deputy Director-General of the RIVM of Bilthoven (NL) | 1993-03-17 | — | — | EP | disclosed |
| WO-1992001474-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |
| US-5034519-A | Ribose, ribitol and phosphate oligosaccharides for vaccines and immunology for haemophilus | DE STAAT DER NEDERLANDEN (NL) | 1991-07-23 | — | — | US | disclosed |
| EP-0276516-A2 | New oligosaccharides, immunogens and vaccines, and methods for preparing such oligosaccharides, immunogens and vaccines | De Staat der Nederlanden, represented by the Deputy Director-General of the RIVM of Bilthoven (NL) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139459-A1 | Conjugates A Polypeptide And A Pentasaccharide | SERPINC1, F13A1, F13B | MGLL 4446/4885GLA 2087/4885 |
| US-20120039843-A1 | CONJUGATES OF A POLYPEPTIDE AND AN OLIGOSACCHARIDE | SERPINC1, SELP, F13B | MGLL 4425/4885GLA 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.